Here is a clear picture of the insulin landscape in Bangladesh as of 2026:
Best Insulin Companies in Bangladesh
1. Eskayef Pharmaceuticals Ltd. (SK+F) - Top Local Producer
The most significant development in Bangladesh's insulin sector is the Eskayef-Novo Nordisk technology transfer partnership, announced recently. This makes Eskayef the first and only local manufacturer of modern insulin in Bangladesh. Under the deal:
- Premix and rapid-acting insulin cartridges are now produced domestically for the first time
- Every batch is verified in Denmark to meet global standards
- Novo Nordisk cut prices by 18% on key products like NovoMix® and NovoRapid® as a result
- This is a major leap from generic drugs into high-value biologics
Eskayef is ranked 6th overall in Bangladesh's pharma market (IQVIA 2025) but is now the leading name specifically in insulin manufacturing.
2. Novo Nordisk (Global Brand, Distributed in Bangladesh)
The Danish giant is the world's largest insulin producer and has deep presence in Bangladesh through its local unit. Its products (NovoRapid®, NovoMix®, Tresiba®, etc.) are widely prescribed. The partnership with Eskayef extends their reach further.
3. Incepta Pharmaceuticals Ltd.
Ranked 2nd overall in Bangladesh's pharma market, Incepta has a strong biotech division and produces insulin locally. It is known for affordable pricing and wide distribution across the country. Many Bangladeshi doctors rely on Incepta's insulin products for price-sensitive patients.
4. Square Pharmaceuticals PLC
Bangladesh's #1 pharma company with ~17-18% market share overall (IQVIA 2025). Square has a broad portfolio that includes insulin products, backed by the country's most extensive distribution network.
5. Opsonin Pharma Ltd.
A well-established generics manufacturer that also produces insulin formulations. Known for affordability and wide reach in rural areas.
Summary Table
| Company | Role | Strength |
|---|
| Eskayef (SK+F) | Local manufacturer (Novo Nordisk partnership) | Only domestic modern insulin producer |
| Novo Nordisk | Global brand, distributed locally | Gold standard quality, widest product range |
| Incepta | Local manufacturer + biotech | Affordable, strong biotech pipeline |
| Square | Local manufacturer | Largest distribution network |
| Opsonin | Generics | Affordable, rural reach |
Bottom line: For quality and innovation, the Eskayef-Novo Nordisk partnership is the most significant development right now. For overall availability and trust, Novo Nordisk branded products remain the market leader, while Incepta is the strongest purely local insulin producer. Bangladesh currently has ~13 million diabetics, projected to reach 22 million by 2045, making this a rapidly growing sector.